StreetAlpha.app
Home › Stocks › ALLO

Allogene Therapeutics, Inc. (ALLO)

Healthcare
Members
LATEST PRICE

Allogene Therapeutics develops engineered T cell treatments from healthy donor cells for cancer and autoimmune diseases. ALLO reports earnings on Thu, Nov 5, 2026. In the past 30 days there were 1 dark pool print.

Prices, price targets and earnings estimates for ALLO are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plans
AI Auto Pilots
Is ALLO in one of our four AI portfolios? Sign in free to see
See how it works→ Details ↓

Earnings

Earnings calendar →
Next report
Nov 5
2026 · Time not announced
Consensus EPS forecast
Members
EPS and revenue estimates
Year-ago EPS
Members
Same quarter last year
Options-implied move
Members
Move priced in by options
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated ALLO in the past 90 days, not enough for a consensus
Average 12-month target
Price targets for ALLOThe average, highest and lowest analyst targets and the target chart are shown to AI Starter and AI Pro members.See plans
Latest rating changes
CitizensReiterated
Aug 17Buy
DateFirmActionRatingPrice target
Aug 17CitizensReiteratedBuy
Loading…

Whale Options Flow

90D

No whale options trades in ALLO in the last 90 days.

Loading…

Dark Pool

30D
Prints
1
Notional
Members
Largest print
Members
Loading…

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ALLO is in one of them and how their past ALLO trades turned out.

See how it works→ View all auto pilots→
ALLO in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ALLO in an article yet. Here's the latest on the wider market.

macronewsFriday, October 30, 2026
Binance and Polymarket Hacks Test Crypto's Plumbing, Not Yet Macro
Binance paused withdrawals after a suspected theft of roughly $6 billion, while Polymarket halted trading for an hour after a vendor breach.
Jean Westart · 3 min read
macronewsMonday, October 26, 2026
S&P 500 Sits 2.5% Below Its Record Ahead of the Fed and Big Tech
The S&P 500 slipped 0.47% to 7,623.68, 2.5% below its record, as the Fed meets October 28 and Alphabet, Microsoft and Amazon report.
Marie Crown · 3 min read
macronewsMonday, October 26, 2026
Hightower's Stephanie Link Tells Investors to Add on Volatility
Hightower's Stephanie Link told CNBC's Squawk Box that investors should use market volatility to add to portfolios as earnings season unfolds.
Adam Landser · 2 min read

About Allogene Therapeutics

Allogene Therapeutics is a biotechnology company based in South San Francisco, California, that develops engineered T cell treatments for cancer and autoimmune diseases. Its treatments are made from healthy donor cells, so they can be prepared ahead of time and given to any eligible patient rather than made from each patient's own cells. Its main candidates target lymphoma, kidney cancer and autoimmune conditions such as lupus, and they are in clinical trials with patients as the intended users.

Headquarters
South San Francisco, CA
Summary based on the company’s 2026 annual report (10-K) ↗